Home
KNSA
KNSA News

Latest Kiniksa Pharmaceuticals Ltd. (KNSA) News on November 19, 2025

MT Newswires

a month ago

Kiniksa Pharmaceuticals Says Pericarditis Treatment Candidate Got US FDA Orphan Drug Designation

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

GlobeNewswire

a month ago

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again

Zacks

a month ago

Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again

RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

Zacks

2 months ago

RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

Zacks

2 months ago

TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

Zacks

2 months ago

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

MT Newswires

2 months ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $3,506,278, According to a Recent SEC Filing

MT Newswires

3 months ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $547,141, According to a Recent SEC Filing

MT Newswires

5 months ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,160,035, According to a Recent SEC Filing

MT Newswires

5 months ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $800,778, According to a Recent SEC Filing

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

GlobeNewswire

5 months ago

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire

6 months ago

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

MT Newswires

7 months ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,265,339, According to a Recent SEC Filing

MT Newswires

7 months ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,347,335, According to a Recent SEC Filing

3 Stocks Including Kiniksa Pharmaceuticals International That May Be Priced Below Intrinsic Value Estimates

Simply Wall St.

7 months ago

3 Stocks Including Kiniksa Pharmaceuticals International That May Be Priced Below Intrinsic Value Estimates

US High Growth Tech Stocks To Watch In April 2025

Simply Wall St.

7 months ago

US High Growth Tech Stocks To Watch In April 2025

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

GlobeNewswire

7 months ago

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

An Intrinsic Calculation For Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Suggests It's 41% Undervalued

Simply Wall St.

7 months ago

An Intrinsic Calculation For Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Suggests It's 41% Undervalued

MT Newswires

7 months ago

Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $36 From $34, Maintains Outperform Rating

MT Newswires

7 months ago

Kiniksa Pharmaceuticals Swings to Q1 Net Income, Revenue Increases

Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates

Zacks

7 months ago

Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

GlobeNewswire

7 months ago

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025: Everything You Need To Know Ahead Of ...

GuruFocus.com

7 months ago

Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025: Everything You Need To Know Ahead Of ...

Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025 Earnings Report Preview: What To Look For

GuruFocus.com

7 months ago

Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025 Earnings Report Preview: What To Look For

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

GlobeNewswire

7 months ago

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

MT Newswires

7 months ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $370,475, According to a Recent SEC Filing

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

Zacks

7 months ago

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?

Zacks

7 months ago

Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?

Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Zacks

7 months ago

Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know

Zacks

7 months ago

Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know

How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%

Zacks

8 months ago

How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

Motley Fool

8 months ago

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

MT Newswires

8 months ago

Citigroup Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $40 Price Target

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now?

Insider Monkey

8 months ago

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now?

Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock

Zacks

9 months ago

Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Zacks

9 months ago

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?

Zacks

9 months ago

Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now?

Insider Monkey

9 months ago

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now?

US High Growth Tech Stocks With Strong Potential

Simply Wall St.

9 months ago

US High Growth Tech Stocks With Strong Potential

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates

Zacks

9 months ago

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

9 months ago

Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire

9 months ago

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

GlobeNewswire

9 months ago

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

GlobeNewswire

9 months ago

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles

The Wall Street Journal

9 months ago

Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles

Exploring High Growth Tech Stocks in the United States

Simply Wall St.

10 months ago

Exploring High Growth Tech Stocks in the United States

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

Zacks

10 months ago

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

GlobeNewswire

10 months ago

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

a year ago

Exploring Three High Growth Tech Stocks In The United States

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

GlobeNewswire

a year ago

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

MT Newswires

a year ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $357,680, According to a Recent SEC Filing

Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025?

Insider Monkey

a year ago

Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025?

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

GlobeNewswire

a year ago

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

Kiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Simply Wall St.

a year ago

Kiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Kiniksa Pharmaceuticals International Third Quarter 2024 Earnings: EPS Misses Expectations

Simply Wall St.

a year ago

Kiniksa Pharmaceuticals International Third Quarter 2024 Earnings: EPS Misses Expectations

Thomson Reuters StreetEvents

a year ago

Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call

Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ...

GuruFocus.com

a year ago

Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ...

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

Zacks

a year ago

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

MT Newswires

a year ago

Kiniksa Pharmaceuticals Q3 Loss Narrows, Revenue Rises

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire

a year ago

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

What To Expect From Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings

GuruFocus.com

a year ago

What To Expect From Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings

Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

GlobeNewswire

a year ago

Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

GlobeNewswire

a year ago

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

High Growth Tech Stocks To Watch In October 2024

Simply Wall St.

a year ago

High Growth Tech Stocks To Watch In October 2024

Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet

Zacks

a year ago

Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet

Baker Bros. Advisors LP Increases Stake in Kiniksa Pharmaceuticals

GuruFocus.com

a year ago

Baker Bros. Advisors LP Increases Stake in Kiniksa Pharmaceuticals

NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

GlobeNewswire

a year ago

NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

MT Newswires

a year ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $437,325, According to a Recent SEC Filing

Top High Growth Tech Stocks To Watch In September 2024

Simply Wall St.

a year ago

Top High Growth Tech Stocks To Watch In September 2024

MT Newswires

a year ago

Jefferies Initiates Kiniksa Pharmaceuticals at Buy With $40 Price Target

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

GlobeNewswire

a year ago

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade

Zacks

a year ago

Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade

Zacks.com featured highlights include Kiniksa Pharmaceuticals, HNI, AudioEye, Balchem and The Gorman-Rupp

Zacks

a year ago

Zacks.com featured highlights include Kiniksa Pharmaceuticals, HNI, AudioEye, Balchem and The Gorman-Rupp

5 Stocks With Recent Price Strength in a Volatile Market

Zacks

a year ago

5 Stocks With Recent Price Strength in a Volatile Market

Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know

Zacks

a year ago

Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know

MT Newswires

a year ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $3,491,947, According to a Recent SEC Filing

Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why

Zacks

a year ago

Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why

MT Newswires

a year ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $601,108, According to a Recent SEC Filing

MT Newswires

a year ago

Kiniksa Pharmaceuticals International Insider Sold Shares Worth $578,966, According to a Recent SEC Filing

Kiniksa Pharmaceuticals International And Two More Firms Possibly Priced Below Market Value Estimates

Simply Wall St.

a year ago

Kiniksa Pharmaceuticals International And Two More Firms Possibly Priced Below Market Value Estimates

MT Newswires

a year ago

Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $34 From $30, Maintains Outperform Rating

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates

MT Newswires

a year ago

Kiniksa Pharmaceuticals Swings to Q2 Loss, Revenue Increases

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire

a year ago

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

GlobeNewswire

a year ago

Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

The 13% return this week takes Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) shareholders three-year gains to 60%

Simply Wall St.

a year ago

The 13% return this week takes Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) shareholders three-year gains to 60%

Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease

GlobeNewswire

a year ago

Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease

MT Newswires

a year ago

Kiniksa Pharmaceuticals Files $400 Million Mixed Shelf

MT Newswires

a year ago

Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday

MT Newswires

a year ago

Kiniksa Pharmaceuticals Signs Deal With Samsung Biologics for Arcalyst Supply

MT Newswires

a year ago

Kiniksa Collaborates With NHL Hall-of-Famer Henrik Lundqvist on Pericarditis Awareness Campaign

Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis

GlobeNewswire

a year ago

Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis

Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative

GlobeNewswire

a year ago

Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

a year ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

a year ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

a year ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

a year ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

a year ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

a year ago

SEALSQ to Launch Two New Quantum Resistant Chips

Share on Social Networks: